303 related articles for article (PubMed ID: 33169938)
1. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis.
Bishnoi R; Xie Z; Shah C; Bian J; Murthy HS; Wingard JR; Farhadfar N
Cancer Med; 2021 Jan; 10(1):70-78. PubMed ID: 33169938
[TBL] [Abstract][Full Text] [Related]
2. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.
Fakhri B; Fiala MA; Shah N; Vij R; Wildes TM
Cancer; 2020 Feb; 126(4):808-813. PubMed ID: 31721140
[TBL] [Abstract][Full Text] [Related]
3. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
[TBL] [Abstract][Full Text] [Related]
4. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib.
Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F
Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833
[TBL] [Abstract][Full Text] [Related]
5. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
Chari A; Hajje D
BMC Cancer; 2014 Dec; 14():915. PubMed ID: 25471129
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib: A Tale of a Heartbreaking Moment: Case Report and Concise Review of the Literature.
Serra W; Fantin A; Longo C; Rabia G; De Rosa F; Plenteda C; Re F; Crisafulli E; Chetta A
Cardiovasc Hematol Disord Drug Targets; 2019; 19(3):253-258. PubMed ID: 30516116
[TBL] [Abstract][Full Text] [Related]
7. Management of Carfilzomib-Associated Cardiac Adverse Events.
Mikhael J
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
[TBL] [Abstract][Full Text] [Related]
8. Once-weekly
Bringhen S; Mina R; Petrucci MT; Gaidano G; Ballanti S; Musto P; Offidani M; Spada S; Benevolo G; Ponticelli E; Galieni P; Cavo M; Di Toritto TC; Di Raimondo F; Montefusco V; Palumbo A; Boccadoro M; Larocca A
Haematologica; 2019 Aug; 104(8):1640-1647. PubMed ID: 30733270
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
[TBL] [Abstract][Full Text] [Related]
11. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
12. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K; Lonial S
Haematologica; 2013 Nov; 98(11):1753-61. PubMed ID: 23935022
[TBL] [Abstract][Full Text] [Related]
13. Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
Chavda SJ; Pocock R; Cheesman S; Lee KM; Dowling E; Marks DJB; Kyriakou C; Lee L; Sive J; Wechalekar A; Rabin N; Yong K; Popat R
Br J Haematol; 2020 Sep; 190(5):e312-e316. PubMed ID: 32535901
[No Abstract] [Full Text] [Related]
14. Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database.
Nakao S; Uchida M; Satoki A; Okamoto K; Uesawa Y; Shimizu T
Oncology; 2022; 100(1):60-64. PubMed ID: 34673654
[TBL] [Abstract][Full Text] [Related]
15. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.
Bringhen S; Milan A; D'Agostino M; Ferri C; Wäsch R; Gay F; Larocca A; Offidani M; Zweegman S; Terpos E; Goldschmidt H; Cavo M; Ludwig H; Driessen C; Auner HW; Caers J; Gramatzki M; Dimopoulos MA; Boccadoro M; Einsele H; Sonneveld P; Engelhardt M
J Intern Med; 2019 Jul; 286(1):63-74. PubMed ID: 30725503
[TBL] [Abstract][Full Text] [Related]
16. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
Chari A; Stewart AK; Russell SD; Moreau P; Herrmann J; Banchs J; Hajek R; Groarke J; Lyon AR; Batty GN; Ro S; Huang M; Iskander KS; Lenihan D
Blood Adv; 2018 Jul; 2(13):1633-1644. PubMed ID: 29991494
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis.
Latif A; Kapoor V; Lateef N; Ahsan MJ; Usman RM; Malik SU; Ahmad N; Rosko N; Rudoni J; William P; Khouri J; Anwer F
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):30-45. PubMed ID: 33845729
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
Waxman AJ; Clasen S; Hwang WT; Garfall A; Vogl DT; Carver J; O'Quinn R; Cohen AD; Stadtmauer EA; Ky B; Weiss BM
JAMA Oncol; 2018 Mar; 4(3):e174519. PubMed ID: 29285538
[TBL] [Abstract][Full Text] [Related]
19. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib.
Zhao F; Yang B; Wang J; Zhang R; Liu J; Yin F; Xu W; He C
Drug Des Devel Ther; 2018; 12():1525-1531. PubMed ID: 29881259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
